Drug intelligence / Profile preview

2,6-diaminopurine

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

2,6-diaminopurine is a small-molecule adenine analogue and purine antimetabolite that can substitute for adenine in nucleic acids, alter Watson–Crick base pairing, and interfere with nucleic acid metabolism. As an unnatural nucleobase, it pairs with thymine in DNA and uracil in RNA via three hydrogen bonds, and has been used experimentally as an antineoplastic agent and as a tool compound to study incorporation of unnatural nucleotides into tRNA, DNA, and RNA.[1][7][16] More recently, 2,6-diaminopurine has been identified as a highly potent, low-toxicity corrector of UGA nonsense mutations, acting by inhibiting the tRNA-specific 2′-O-methyltransferase FTSJ1, reducing Cm34 methylation of tRNA(Trp), and thereby promoting selective translational readthrough of UGA premature stop codons in cellular and mouse models; this makes it a candidate for treating genetic diseases caused by UGA nonsense mutations and has also shown antitumor activity in TP53 UGA-mutant xenografts.[1][4]

Other names
2-aminoadenine7H-purine-2,6-diamine9H-purine-2,6-diaminepurine-2,6-diamine2,6-diamino-purin-9-yl
02

Targets

FTSJ1

Beyond the preview

Go deeper on 2,6-diaminopurine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2,6-diaminopurine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call